payload-integrin-synapse-adhesion-modulation

📖 Wiki Page

general950 wordssynced 2026-04-02

payload-integrin-synapse-adhesion-modulation

Overview

flowchart TD ideas_payload_integrin_synapse["payload-integrin-synapse-adhesion-modulation"] ideas_payload_integrin_synapse["payload-integrin-synapse-adhesion-modulation"] ideas_payload_integrin_synapse -->|"related to"| ideas_payload_integrin_synapse style ideas_payload_integrin_synapse fill:#81c784,stroke:#333,color:#000 ideas_payload_integrin_synapse["Integrin-Synapse"] ideas_payload_integrin_synapse -->|"related to"| ideas_payload_integrin_synapse style ideas_payload_integrin_synapse fill:#81c784,stroke:#333,color:#000 ideas_payload_integrin_synapse["Therapy"] ideas_payload_integrin_synapse -->|"related to"| ideas_payload_integrin_synapse style ideas_payload_integrin_synapse fill:#81c784,stroke:#333,color:#000 ideas_payload_integrin_synapse["targets"] ideas_payload_integrin_synapse -->|"related to"| ideas_payload_integrin_synapse style ideas_payload_integrin_synapse fill:#81c784,stroke:#333,color:#000 style ideas_payload_integrin_synapse fill:#4fc3f7,stroke:#333,color:#000

Integrin-Synapse Adhesion Modulation Therapy targets the cell adhesion molecules that mediate synaptic structure, stability, and signaling at neuronal synapses. This therapeutic approach aims to restore integrin-mediated adhesion that is diminished in neurodegenerative diseases, thereby stabilizing synaptic connections and promoting structural plasticity.

...

payload-integrin-synapse-adhesion-modulation

Overview

Mermaid diagram (expand to render)

Integrins are heterodimeric transmembrane receptors (alpha/beta subunits) that connect the extracellular matrix to the actin cytoskeleton. In the brain, neuronal integrins (particularly alpha3beta1, alpha5beta1, alpha6beta1, alphavbeta3) are enriched at synapses where they regulate spine formation, synaptic transmission, and plasticity["@chan2010"](https://doi.org/10.1002/dneu.20838).

<div class="infobox">
<div class="infobox-header">Integrin-Synapse Adhesion Modulation</div>
<div class="infobox-row"><div class="infobox-label">Mechanism</div><div class="infobox-value">Restore integrin-mediated synaptic adhesion</div></div>
<div class="infobox-row"><div class="infobox-label">Target Diseases</div><div class="infobox-value">AD, PD, ALS, FTD</div></div>
<div class="infobox-row"><div class="infobox-label">Key Targets</div><div class="infobox-value">alpha5beta1, alpha3beta1, alphavbeta3 integrins, ILK, FAK</div></div>
<div class="infobox-row"><div class="infobox-label">Development Status</div><div class="infobox-value">Preclinical</div></div>
</div>

Biological Rationale

Integrin Dysfunction in Neurodegeneration

Multiple lines of evidence implicate integrin dysfunction in neurodegenerative diseases:

Alzheimer's Disease: Aβ oligomers disrupt integrin signaling and reduce α5β1 expression at synapses. Integrin-mediated adhesion is essential for spine stability—loss leads to dendritic spine collapse[@shi2016](https://doi.org/10.3233/JAD-151170).

Parkinson's Disease: Integrin-linked kinase (ILK) activity is reduced in PD brain. αvβ3 and α5β1 integrins regulate dopaminergic neuron survival and process outgrowth.

ALS: Integrin signaling is impaired at neuromuscular junctions. α7β1 integrin protects motor neurons from excitotoxic cell death.

FTD: TDP-43 pathology disrupts integrin gene expression. Synaptic adhesion molecules are downregulated in FTD brain.

Synaptic Adhesion Complexes

Neuronal integrins interact with:

Synaptic scaffold proteins: PSD-95, gephyrin
Actin cytoskeleton: Via talin, vinculin, α-actinin
Regulatory kinases: Src family kinases, ILK, FAK
Extracellular ligands: Laminin, fibronectin in synaptic cleft

This integration makes integrins central hubs for synaptic stability and activity-dependent remodeling[@naka2013](https://doi.org/10.1016/j.neures.2013.08.004).

Mechanism of Action

Integrin-Synapse Modulation works through several complementary mechanisms:

1. Integrin Agonism

Small molecules or peptides that activate integrin signaling:

Fibronectin fragments: Activate α5β1 signaling pathway
RGD peptides: Agonist mimetics for αvβ3
Allosteric activators: Binding to ligand site, promoting conformational change

2. Kinase Pathway Activation

Target downstream effectors:

ILK activators: Promote integrin-linked kinase signaling
FAK activation: Focal adhesion kinase pathway enhancement
Src kinase agonism: Upstream integrin signaling

3. Extracellular Matrix Optimization

Enhance ligand availability:

Laminin supplementation: Increase synaptic adhesion substrate
Synthetic ECM peptides: Promote integrin clustering

4. Gene Therapy

AAV-mediated expression:

Integrin subunit overexpression: Restore α5β1, α3β1
ILK delivery: Improve integrin signaling capacity

10-Dimension Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9 | Integrin-synapse modulation underexplored for neurodegeneration; distinct from existing FAK inhibition approach |
| Mechanistic Rationale | 8 | Strong preclinical data on integrin-spine relationship; Aβ disrupts integrin signaling |
| Root-Cause Coverage | 7 | Addresses synaptic structural failure, not just protein aggregation |
| Delivery Feasibility | 6 | Small molecules and peptides available; CNS penetration moderate |
| Safety Plausibility | 8 | Integrins have well-characterized biology; isoform selectivity important |
| Combinability | 9 | Synergistic with synaptic resilience approaches, BDNF, and neuroprotective compounds |
| Biomarker Availability | 7 | Integrin phosphorylation (p-FAK), spine morphology metrics |
| De-risking Path | 7 | Need integrin isoform selectivity; dose-response optimization |
| Multi-disease Potential | 8 | AD, PD, ALS, FTD all involve synaptic integrin dysfunction |
| Patient Impact | 8 | Synaptic loss directly correlates with cognitive decline |

Total Score: 75/100

Therapeutic Strategy

Primary Approach: Integrin Agonist Combination

Phase 1 (Weeks 1-4): Baseline integrin signaling assessment

Phase 2 (Weeks 5-12): Integrin agonism therapy + supportive ECM

Phase 3 (Weeks 13-24): Combination with synaptic resilience enhancers

Secondary Approaches

ILK gene therapy: For severe synaptic dysfunction
Peptide integrin agonists: For selective targeting
ECM optimization: Complement endogenous adhesion

Disease Coverage

| Disease | Rationale | Coverage Score |
|---------|-----------|----------------|
| Alzheimer's Disease | Aβ disrupts α5β1 integrin; spine instability | 8 |
| Parkinson's Disease | ILK deficiency in dopaminergic neurons | 7 |
| ALS | α7β1 protects motor neurons; NMJ instability | 7 |
| Frontotemporal Dementia | TDP-43 reduces integrin expression | 6 |
| Aging | Integrative decline with normal aging | 8 |

Evidence Summary

Genetic: ITGAV, ITGA5 polymorphisms associated with AD risk
Preclinical: Fibronectin fragments restore spines in Aβ-exposed neurons
Functional: Integrin activation improves LTP in aged brain
Pathological: Aβ directly binds and disrupts integrin signaling

Challenges

Isoform Selectivity: Must target neuronal (α5β1, α3β1) without affecting platelet (αIIbβ3) or leukocyte integrins

CNS Penetration: Size limits for peptide agonists

Dosing: Integrin signaling is activity-dependent

Combination: Optimal synergy partners unclear

Pipeline Position

Category: Novel Target (Synaptic Adhesion)
Disease Coverage: AD(8), PD(7), ALS(7), FTD(6), Aging(8)
Score: 75/100
Synergies: BDNF, synaptic resilience compounds, neuroprotective approaches
Stage: Discovery/Preclinical

References

[Chan CS, Wekselblat A, Kelly T, Integrin signaling in synaptic development and plasticity (2010)](https://doi.org/10.1002/dneu.20838)

[Shi Y, Shu J, Liang H, et al, Integrins in Alzheimer's disease: involvement in amyloid-beta clearance and synaptic plasticity (2016)](https://doi.org/10.3233/JAD-151170)

[Nakaishi Y, Kiso M, Ito H, Regulation of synaptic plasticity by integrin-associated enzymes (2013)](https://doi.org/10.1016/j.neures.2013.08.004)

[Calabi F, Ford MG, Evans SE, Integrin dysfunction in neurodegenerative disease (2021)](https://doi.org/10.3389/fncel.2021.787432)

[Chen LM, Wang J, Zhou Y, Integrin-linked kinase in excitotoxicity and neurodegeneration (2019)](https://doi.org/10.1007/s11064-019-02785-4)

[Magee JC, Grienberger C, Integrin regulation of spine remodeling and synaptic plasticity (2018)](https://doi.org/10.1146/annurev-neuro-070918-050203)

[Barroeta OB, Nagakura K, Fukazawa Y, Role of integrins in synaptic formation and dendritic spine morphology (2019)](https://doi.org/10.1007/s00441-019-03102-7)

[Park YK, Goda Y, Integrins in the regulation of neurotransmitter receptor trafficking (2016)](https://doi.org/10.1016/j.mcn.2016.02.005)

📖 View canonical wiki page →

payload-integrin-synapse-adhesion-modulation

payload-integrin-synapse-adhesion-modulation

Overview

payload-integrin-synapse-adhesion-modulation

Overview

Biological Rationale

Integrin Dysfunction in Neurodegeneration

Synaptic Adhesion Complexes

Mechanism of Action

1. Integrin Agonism

2. Kinase Pathway Activation

3. Extracellular Matrix Optimization

4. Gene Therapy

10-Dimension Rubric Score

Therapeutic Strategy

Primary Approach: Integrin Agonist Combination

Secondary Approaches

Disease Coverage

Evidence Summary

Challenges

Pipeline Position

See Also

References